Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?
Early TAVR for asymptomatic severe AS cuts costs, improves outcomes
The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.
Winning cash for taking blood pressure meds increases compliance
About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.
SCAI: Noncompete contracts unfairly bind cardiologists to hospitals unless they move
"These provisions are contained in what amounts, in many cases, to contracts of adhesion, because a physician’s only choice is to accept the terms of the contract without revision or else forgo employment," the Society for Cardiovascular Angiography and Interventions wrote to the U.S. Federal Trade Commission.

Beta-blockers do not benefit heart attack patients with a normal LVEF

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Early TAVR for asymptomatic severe AS cuts costs, improves outcomes

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

Winning cash for taking blood pressure meds increases compliance

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

SCAI: Noncompete contracts unfairly bind cardiologists to hospitals unless they move

"These provisions are contained in what amounts, in many cases, to contracts of adhesion, because a physician’s only choice is to accept the terms of the contract without revision or else forgo employment," the Society for Cardiovascular Angiography and Interventions wrote to the U.S. Federal Trade Commission.

Society of Cardiovascular Angiography and Interventions (SCAI) President Srihari S. Naidu, MD, professor of medicine at New York Medical College, explains the SCAI initiative to improve outcomes in cardiogenic shock by monitoring and lowering patient lactate levels.

SCAI: To improve cardiogenic shock outcomes, reduce lactate levels

SCAI feels this is the best way forward to try lowering mortality rates, but the group is asking cardiologists to help by gathering more data.

Drinking coffee may reduce risk of recurrent AFib

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

AI-enabled coronary plaque quantification outperforms traditional risk scores

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.